Genome Engineering Market Size, Share, Forecasts Analysis, Company Growth, Company Profiles and Key Regions 2025
Genome Engineering Market |
The strategies and procedures used to modify the target genetic information of any living organism are referred to as genomic engineering. Due to the wide variety of applications in fields such as gene mutations, medicines, and agricultural biotechnology, the genomic engineering market is quickly expanding.
The high cost of genome engineering technologies is projected to be a major stumbling block to the market's growth over the forecast period. For example, according to the Yale Genome Editing Center's price schedule, gene editing services cost between US$ 8,000 and US$ 15,000 in 2018. The high cost of genome engineering facilities is projected to stifle Genome Engineering Market expansion, particularly in emerging markets like India, Brazil, and South Africa. Furthermore, genome engineering is a highly difficult technology that necessitates highly qualified researchers, limiting its applicability.
Market expansion is also predicted to be fueled by increased financing and investments for the development and study of novel genetic engineering technologies. In January 2018, the National Institutes of Health (NIH) in the United States announced a grant of US$ 190 million for genome editing research. Over the next six years, this new programme, Somatic Cell Genome Editing, will give cash to scientific researchers. The funding of major research institutions such as the National Institutes of Health (NIH) is projected to attract more researchers to this subject, which could lead to technological breakthroughs and market growth.
Market Segmentation:
by technology:
by application:
by end user:
The key players operating in the genome engineering market include Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis S.A., and Merck Group.
by technology:
- CRISPR/Cas9
- TALEN (Transcription activator like effector nucleases)
- Zinc Finger Nuclease
- Others (Anti-sense and Recombinant Adeno-Associated Virus)
by application:
- Cell Line Engineering
- Genetic Engineering
by end user:
- Pharmaceutical and Biotechnological Companies
- Research and Academic Institutions
- Clinical Research Organizations
The key players operating in the genome engineering market include Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis S.A., and Merck Group.
Comments
Post a Comment